0001604950-17-000001.txt : 20170106 0001604950-17-000001.hdr.sgml : 20170106 20170106160830 ACCESSION NUMBER: 0001604950-17-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20170106 DATE AS OF CHANGE: 20170106 EFFECTIVENESS DATE: 20170106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: scPharmaceuticals Inc. CENTRAL INDEX KEY: 0001604950 IRS NUMBER: 465184075 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-277857 FILM NUMBER: 17514408 BUSINESS ADDRESS: STREET 1: 75 ARLINGTON STREET STREET 2: SUITE 500 CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 617-517-0730 MAIL ADDRESS: STREET 1: 75 ARLINGTON STREET STREET 2: SUITE 500 CITY: BOSTON STATE: MA ZIP: 02116 D 1 primary_doc.xml X0707 D LIVE 0001604950 scPharmaceuticals Inc. 131 Hartwell Avenue Suite 215 Lexington MA MASSACHUSETTS 02421 617-517-0730 DELAWARE None None Corporation true 2013 Pieter Muntendam 131 Hartwell Avenue Suite 215 Lexington MA MASSACHUSETTS 02421 Executive Officer Director Kush Parmar 131 Hartwell Avenue Suite 215 Lexington MA MASSACHUSETTS 02421 Director Mette Agger 131 Hartwell Avenue Suite 215 Lexington MA MASSACHUSETTS 02421 Director Leonard Schaeffer 131 Hartwell Avenue Suite 215 Lexington MA MASSACHUSETTS 02421 Director Dorothy Coleman 131 Hartwell Avenue Suite 215 Lexington MA MASSACHUSETTS 02421 Director Jack Khattar 131 Hartwell Avenue Suite 215 Lexington MA MASSACHUSETTS 02421 Director Abraham Ceesay 131 Hartwell Avenue Suite 215 Lexington MA MASSACHUSETTS 02421 Executive Officer Troy Ignelzi 131 Hartwell Avenue Suite 215 Lexington MA MASSACHUSETTS 02421 Executive Officer Jonathan Silverstein 131 Hartwell Avenue Suite 215 Lexington MA MASSACHUSETTS 02421 Director Abhay Gandhi 131 Hartwell Avenue Suite 215 Lexington MA MASSACHUSETTS 02421 Director Pharmaceuticals Decline to Disclose 06b false 2016-12-22 false true false 0 46962788 46962788 0 From the Total Offering Amount approximately $41,000,000 was from new shares of Series B stock sold and $5,962,788 was from the conversion of debt into Series B stock. false 11 0 0 0 false scPharmaceuticals Inc. /s/ Troy Ignelzi Troy Ignelzi Chief Financial Officer 2017-01-06